Reference

1. Re, F.; Gregori, M.; Masserini, M. Nanotechnology for neurodegenerative disorders. Maturitas 2012, 73, 45–51. [CrossRef] [PubMed]
2. Gitler, A.D.; Dhillon, P.; Shorter, J. Neurodegenerative Disease: Models, Mechanisms, and a New Hope; The Company of Biologists Ltd.: Cambridge, UK, 2017; Volume 10, pp. 499–502.
3. WHO.TheTop10Causes of Death-WHO|World Health Organization; WHO: Geneva, Switzerland, 2020. Available online: https: //www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 12 January 2022).
4. W.M.Pardridge, The blood–brain barrier: bottleneck in brain drug development, NeuroRx 2 (2005) 3–14.
5. D.J. Begley, Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmacol. Ther. 104 (2004) 29–45.
6. Ramos-Cabrer, P.; Agulla, J.; Argibay, B.; Pérez-Mato, M.; Castillo, J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int. J. Pharm. 2011, 405, 228–233. [CrossRef] [PubMed]
7. El-aziz, E.A.E.-d.A.; Elgayar, S.F.; Mady, F.M.; Abourehab, M.A.; Hasan, O.A.; Reda, L.M.; Alaaeldin, E. The Potential of Optimized Liposomes in Enhancement of Cytotoxicity and Apoptosis of Encapsulated Egyptian Propolis on Hep-2 Cell Line. Pharmaceutics 2021, 13, 2184. [CrossRef]
8. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood–brain barrier. Neurobiol. Dis. 2010, 37, 13–25. [CrossRef] [PubMed]
9. De Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology 1997; 48: 1277–81.
10. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. Howcommonarethe“common” neurologic disorders? Neurology 2007:68(5):326–327. Doi:10.1212/01.wnl.0000252807.38124.a3.
11. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459–80.
12. Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin 2016; 34: 955–65.
13. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschrift Psychiatr 1907; 64: 146–148.
14. Alzheimer Europe. Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. 2020. https://www.alzheimereurope.org/content/download/195515/1457520/file/FINAL 05707 Alzheimer Europe yearbook 2019.pdf (accessed Jan 24, 2021).
15. Wu Y-T, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol 2016; 15: 116124.
16. Matthews FE, Stephan BCM, Robinson L, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun 2016; 7: 11398.
17. Prince M, Albanese E, Guerchet M, et al. World Alzheimer Report 2014: Dementia and Risk Reduction an Analysis of Protective and Modifiable Factors, 2014.
18. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475–82.
19. Saxena S, Li S. Defeating epilepsy: A global public health commitment. Epilepsia Open 2017; 2: 153–55.
20. Megiddo I, Colson A, Chisholm D, Dua T, Nandi A, Laxminarayan R. Health and economic benefits of public financing of epilepsy treatment in India: An agentbased simulation model. Epilepsia 2016; 57: 464–74.
21. Ding D, Hong Z, Chen GS, et al. Primary care treatment of epilepsy with phenobarbital in rural China: costoutcome analysis from the WHO/ILAE/IBE global campaign against epilepsy demonstration project. Epilepsia 2008; 49: 535–39.
22. WHO. Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications. 2015: Resolution WHA68·20.
23. Lancet 2007; 369: 218–28 Department of Neurology, Wake Forest University, Medical Center Blvd, Winston Salem, NC 27157, USA (Prof F O Walker MD) fwalker@wfubmc.edu
24. Lancet Neurol 2005; 4: 635–42 Pathology 627, The Johns Hopkins University School of Medicine & Bloomberg School of Public Health, Baltimore, MD21287, USA (R TJohnsonMD) rtj@jhmi.edu
25. Marianecci, C., Rinaldi, F., Hanieh, P. N., Di Marzio, L., Paolino, D., & Carafa, M. (2017). Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting. Drug Design, Development and Therapy, Volume11, 325–335. https://doi.org/10.2147/DDDT.S100075
26. Bors, L., & Erd?, F. (2019). Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery. Scientia Pharmaceutica, 87(1), 6. https://doi.org/10.3390/scipharm87010006
27. Denora, N., Trapani, A., Laquintana, V., Lopedota, A., & Trapani, G. (2009). Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain. Current Topics in Medicinal Chemistry, 9(2), 182–196. https://doi.org/10.2174/156802609787521571
28. De Pablo, F., & de la Rosa, E. J. (1995). The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends in Neurosciences, 18(3), 143–150. https://doi.org/10.1016/01662236(95)93892-2
29. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3(8), 711–716. https://doi.org/10.1038/nrd1470
30. Akhtar, A., Andleeb, A., Waris, T. S., Bazzar, M., Moradi, A.-R., Awan, N. R., & Yar, M. (2021). Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. Journal of Controlled Release, 330, 1152–1167. https://doi.org/10.1016/j.jconrel.2020.11.021
31. Wang,L.-S.; Chuang, M.-C.; Ho, J.-a.A. Nanotheranostics—A review of recent publications. Int. J. Nanomed. 2012, 7, 4679.
32. Shim, M.S.; Kwon, Y.J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv. Drug Deliv. Rev. 2012, 64, 1046–1059. [CrossRef]
33. Ramos-Cabrer, P.; Agulla, J.; Argibay, B.; Pérez-Mato, M.; Castillo, J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int. J. Pharm. 2011, 405, 228–233. [CrossRef] [PubMed]
34. Fontes, M.A.P.; Vaz, G.C.; Cardoso, T.Z.D.; de Oliveira, M.F.; Campagnole-Santos, M.J.; Dos Santos, R.A.S.; Sharma, N.M.; Patel, K.P.; Frézard, F. GABA-containing liposomes: Neuroscience applications and translational perspectives for targeting neurological diseases. Nanomed. Nanotechnol. Biol. Med. 2018, 14, 781–788. [CrossRef]
35. Frézard, F.; dos Santos, R.A.; Fontes, M.A. Liposome-encapsulated neuropeptides for site-specific microinjection. In Neuropeptides; Springer: Berlin/Heidelberg, Germany, 2011; pp. 343–355.
36. Ulrich, A.S. Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep. 2002, 22, 129–150. [CrossRef]
37. Spuch, C.; Navarro, C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J. Drug Deliv. 2011, 2011, 469679. [CrossRef]
38. Hanson, L. R., & Frey, W. H. (2008). Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience, 9(S3), S5. https://doi.org/10.1186/1471-2202-9-S3-S5
39. Lochhead, J. J., & Thorne, R. G. (2012). Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews, 64(7), 614–628. https://doi.org/10.1016/j.addr.2011.11.002
40. Denora, N., Trapani, A., Laquintana, V., Lopedota, A., & Trapani, G. (2009). Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain. Current Topics in Medicinal Chemistry, 9(2), 182–196. https://doi.org/10.2174/156802609787521571
41. Kumar,A.; Singh, A. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015, 67, 195–203. [CrossRef]
42. Furtado, D.; Björnmalm, M.; Ayton, S.; Bush, A.I.; Kempe, K.; Caruso, F. Overcoming the blood–brain barrier: The role of nanomaterials in treating neurological diseases. Adv. Mater. 2018, 30, 1801362. [CrossRef] [PubMed]
43. Li, A.; Tyson, J.; Patel, S.; Patel, M.; Katakam, S.; Mao, X.; He, W. Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease. Front. Bioeng. Biotechnol. 2021, 9, 672594. [CrossRef] [PubMed]
44. Sood, S.; Jain, K.; Gowthamarajan, K. Intranasal therapeutic strategies for management of Alzheimer’s disease. J. Drug Target. 2014, 22, 279–294. [CrossRef] [PubMed]
45. Agarwal, M.; Alam, M.R.; Haider, M.K.; Malik, M.; Kim, D.-K. Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology. Nanomaterials 2021, 11, 59. [CrossRef
46. American Psychiatric Association, A. Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric Association: Washington, DC, USA, 1980; Volume 3.
47. Colvert, E.; Tick, B.; McEwen, F.; Stewart, C.; Curran, S.R.; Woodhouse, E.; Gillan, N.; Hallett, V.; Lietz, S.; Garnett, T. Heritability of autism spectrum disorder in a UK population-based twin sample. JAMA Psychiatry 2015, 72, 415–423. [CrossRef]
48. Hua, X.; Thompson, P.M.; Leow, A.D.; Madsen, S.K.; Caplan, R.; Alger, J.R.; O’Neill, J.; Joshi, K.; Smalley, S.L.; Toga, A.W. Brain growth rate abnormalities visualized in adolescents with autism. Hum. Brain Mapp. 2013, 34, 425–436. [CrossRef]
49. Moni, M.; Rahman, M.; Begum, M.; Uddin, M.; Ashraf, G.M. Deciphering the Role of Nanoparticle-Based Treatment for Parkinson’s Disease. Curr. Drug Metab. 2021, 22, 550–560. [CrossRef]
50. Li, J.; Cai, S.; Zeng, C.; Chen, L.; Zhao, C.; Huang, Y.; Cai, W. Urinary exosomal vitronectin predicts vesicoureteral reflux in patients with neurogenic bladders and spinal cord injuries. Exp. Ther. Med. 2022, 23, 65. [CrossRef]
51. Huang, R.; Boltze, J.; Li, S. Strategies for improved intra-arterial treatments targeting brain tumors: A systematic review. Front. Oncol. 2020, 10, 1443. [CrossRef]
52. Beccaria, K.; Canney, M.; Bouchoux, G.; Puget, S.; Grill, J.; Carpentier, A. Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: A review and perspectives. Neurosurg. Focus 2020, 48, E10. [CrossRef]
53. Huang, R.; Boltze, J.; Li, S. Strategies for improved intra-arterial treatments targeting brain tumors: A systematic review. Front. Oncol. 2020, 10, 1443. [CrossRef]
54. Chen, E.M.; Quijano, A.R.; Seo, Y.-E.; Jackson, C.; Josowitz, A.D.; Noorbakhsh, S.; Merlettini, A.; Sundaram, R.K.; Focarete, M.L.; Jiang, Z. Biodegradable PEG-poly (?-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials 2018, 178, 193–203. [CrossRef]